Latest News - Merck KGaA
Top Corporates Hub
Merck KGaA
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
20.02.2026 17:05
BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.
No one-trick pony in oncology, Merck’s cancer footprint is expanding
20.02.2026 08:00
The three key therapeutic approaches Merck is leveraging to craft its next era in cancer care.
Where is Merck & Co., Inc. (MRK) Headed According to the Street?
19.02.2026 14:52
Merck & Co., Inc. (NYSE:MRK) is one of the best immunotherapy stocks to buy according to hedge funds. On February 13, Merck & Co., Inc. (NYSE:MRK) was upgraded to Buy from Hold by Deutsche Bank, with the firm raising the price target to $150 from $115 and telling investors that it believes the market is […]
AtaiBeckley names Michael Faerm as finance chief
19.02.2026 13:21
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25...
3D Protein Structure Analysis Market Report 2026 Featuring Profiles of Merck, Bruker Corp., Thermo Fisher Scientific, JEOL, Spectris and Other Leading Players
19.02.2026 12:24
The global 3D protein structure analysis market is rapidly expanding due to growing demand in drug development, personalized medicine, and biotech research. Key opportunities include advancements in AI and cloud computing, increased R&D investment, and strategic growth in Asia-Pacific. 3D Protein Structure Analysis Market 3D Protein Structure Analysis Market Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "3D Protein Structure Analysis: Global Markets" has been added to ResearchAndMarkets.com's of
$19.8 Billion Cell and Gene Therapy Tools & Reagents Market Outlook, 2030 Featuring Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, Sartorius and More
19.02.2026 12:22
Emerging technologies, increasing focus on R&D, and a growing demand in treating previously incurable diseases present significant opportunities across diverse applications and regions Cell & Gene Therapy Tools and Reagents Market Cell & Gene Therapy Tools and Reagents Market Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for cell and gene therapy tools and reagents is
MSD and Mayo Clinic team up to advance AI in drug development
19.02.2026 10:46
MSD will integrate clinical insights and genomic datasets from Mayo Clinic Platform, aggregating data in a secure environment.
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
19.02.2026 10:15
RAHWAY, N.J., February 19, 2026--Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 at Increased Risk for Severe RSV Over Two RSV Seasons
Merck & Co. Inc. (NYSE:MRK) Emerges as a Strong Dividend Contender Through Methodical Screening
19.02.2026 09:41
Merck (MRK) offers a strong 2.85% dividend yield with a reliable history of increases, backed by robust profitability and solid financial health for income investors.
Merck Discloses Positive Data For Respiratory Syncytial Virus Antibody Treatment, Seeks FDA Nod For Broader Child Use
19.02.2026 08:56
Merck reports positive RSV trial data, eyes expanded FDA use in children as shares trade near 52-week highs.
Merck Announced Second RSV Season Findings From The Phase 3 Smart Trial (MK-1654-007) Of Enflonsia (Clesrovimab) In Infants And Children At Increased Risk For Severe Respiratory Syncytial Virus Disease Over Two Seasons
19.02.2026 06:33
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive second RSV season findings from the Phase 3 SMART trial (MK-1654-007) (NCT04938830) evaluating the safety, efficacy and
Moderna stock surges as FDA reverses course, agrees to review new flu shot
18.02.2026 16:20
Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.
Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech
18.02.2026 16:03
The cancer vaccine market presents opportunities in personalized and therapeutic vaccines, innovations in delivery strategies, and combination therapies. Collaborations and licensing by key players like Moderna, Merck, and IO Biotech drive industry progression. Challenges remain in broadening efficacy and optimizing delivery platforms.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Cancer Vaccines - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. This report offe
Merck & Co. (MRK) Advances on Robust Keytruda Sales and Positive Clinical Trial Results
18.02.2026 15:17
Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile during the quarter amid concerns over elevated valuations and financing for large-scale data center investments, although the portfolio modestly outperformed the Russell 1000 benchmark […]
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
18.02.2026 11:45
RAHWAY, N.J., & ROCHESTER, Minn., February 18, 2026--Merck and Mayo Clinic today announced a R&D agreement to apply artificial intelligence (AI), advanced analytics and data to support drug discovery.
$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)
18.02.2026 10:16
The global active pharmaceutical ingredients (API) market is poised to reach USD 198.39 billion by 2030, witnessing a CAGR of 6.6% from USD 144.20 billion in 2025. The API market's growth is significantly driven by expanding oncology, rare disease, and diabetes pipelines, bolstered by peptide-based drugs like Semaglutide. In 2024, the pharmaceutical and biotechnology segment captured the largest market share, reinforced by in-house manufacturing of high-value drugs and increasing outsourcing for
The Patent Cliff Is a Hill: Why Merck's Diversification Engine Makes MRK a Buy
18.02.2026 08:06
Diversification Beyond the Keytruda Cliff
Merck And Mayo Clinic Announce R&D Agreement To Apply AI, Advanced Analytics And Multimodal Clinical Data To Support Drug Discovery And Development
18.02.2026 07:46
Strategic collaboration brings together Mayo Clinic's extensive clinical insights, genomic data and Platform architecture with Merck's artificial intelligence (AI) and machine learning (ML) research capabilitiesMerck
Merck Indicates Better Growth Visibility in Post-Keytruda LOE Period
16.02.2026 16:45
MRK outlines solid long-term outlook with more than $70B opportunity beyond Keytruda LOE, backed by pipeline progress, new product launches and M&A deals.